May 2020 CBPP Spotlight

Adding a subcutaneous formulation of daratumumab to the triplet regimen cyclophosphamide, bortezomib, and dexamethasone may hold promise for patients with newly diagnosed light chain amyloidosis who are in urgent need of new treatment options, according to a clinical trial.

Leslie M. Randall, MD, MAS, discussed the treatment regimens available for an African American patient with ovarian cancer.

Robert A. Vescio, MD, discussed two treatment options for a 51-year-old male patient with newly diagnosed multiple myeloma.

Alicia K. Morgans, MD, MPH, discussed treatment and testing strategies for metastatic castration-resistant prostate cancer.

In a Targeted Oncology case-based peer perspectives live discussion, David H. Ilson, MD, PhD, discusses the treatment options for patients with hepatocellular carcinoma

Jeffrey Matous, MD, discussed strategies for treating a 51-year-old male patients with transplant-ineligible multiple myeloma, during a live Targeted Oncology case-based peer perspectives conversation with other experts.

Joshua K. Sabari, MD, goes through treatment options in the frontline and second-line for patients with non–small cell lung cancer in a Targeted Oncology case-based peer perspectives live discussion.

In a Targeted Oncology case-based peer perspectives live discussion, David Gerber, MD, addresses the role of biomarkers in guiding treatment decisions for patients with non–small cell lung cancer based on a patient scenario.